Instrument Inactif

Communiqués Human Genome Sciences

Actions

US4449031081

Recherche biotechnologique et médicale

Cours en clôture Nasdaq
- ^USD	-

25/07/12	GlaxoSmithKline plc : GlaxoSmithKline-T2 inférieur aux attentes, baisse du titre	RE
16/07/12	GSK rachète Human Genome pour 3,0 milliards de dollars	RE

Communiqués

03/08/12	Human Genome Sciences : ANNOUNCES REQUIRED OFFER TO REPURCHASE IN RESPECT OF ITS 3.00% CONVERTIBLE SENIOR NOTES DUE 2018	PU
26/07/12	Human Genome Sciences : Securities Lawyers at Goldfarb LLP Seeking More Money, Information for Stockholders of Human Genome Sciences, Inc.	PR
20/07/12	Human Genome Sciences : Law Offices of Howard G. Smith Announces Investigation of Human Genome Sciences Inc. Board of Directors for Potential Breaches of Fiduciary Duty	BU
18/07/12	Human Genome Sciences : Law Office of Brodsky & Smith, LLC Announces Investigation of Human Genome Sciences, Inc.	PR
17/07/12	Human Genome Sciences : Ryan & Maniskas, LLP Announces Investigation of Human Genome Sciences Inc.	BU
16/07/12	Human Genome Sciences : The Law Firm of Levi & Korsinsky, LLP Announces Investigation into Possible Breaches of Fiduciary Duty by the Board of Human Genome Sciences, Inc. in Connection with the Sale of the Company to GlaxoSmithKline plc	BU
16/07/12	Human Genome Sciences : GSK to acquire Human Genome Sciences for US$14.25 per share in cash	BU
11/07/12	Human Genome Sciences : FYI From Human Genome Sciences: GlaxoSmithKline Announces Positive Data from Harmony 8 Phase 3 Trial and Completion of Clinical Registration Package for Albiglutide in Type 2 Diabetes	BU
10/07/12	Human Genome Sciences : Announces Resubmission of Raxibacumab BLA to FDA	BU
29/06/12	Human Genome Sciences : Responds To GSK Extension of Unsolicited Tender Offer	BU
15/06/12	Human Genome Sciences : REPEAT/Human Genome Sciences Announces July 16 as the Date for Submission of Definitive Acquisition Proposals	BU
15/06/12	Human Genome Sciences : Announces July 16 as the Date for Submission of Definitive Acquisition Proposals	BU
09/06/12	Human Genome Sciences : FYI from Human Genome Sciences: GlaxoSmithKline Announces New Data from Phase 3 Studies of Once-Weekly Albiglutide in Type 2 Diabetes	BU
08/06/12	Human Genome Sciences : Responds to GSK Extension of Unsolicited Tender Offer	BU
06/06/12	Human Genome Sciences : Announces Multiple Abstracts Related to BENLYSTA® and Systemic Lupus Erythematosus to Be Presented at the 2012 EULAR Annual European Congress of Rheumatology	BU
04/06/12	Human Genome Sciences : Invites Investors to Listen to Webcast of Presentation at Goldman Sachs Conference	BU
01/06/12	Human Genome Sciences : Response to GSK Press Release	BU
17/05/12	Human Genome Sciences : ANNOUNCES ADOPTION OF SHORT-TERM STOCKHOLDER RIGHTS PLAN	PU
17/05/12	Human Genome Sciences : Board of Directors Unanimously Determines GlaxoSmithKline Unsolicited Tender Offer is Inadequate and Not in the Best Interests of Stockholders	BU
09/05/12	Human Genome Sciences : Board of Directors to Review Unsolicited Tender Offer From GlaxoSmithKline	BU
24/04/12	Human Genome Sciences : Announces First Quarter 2012 Financial Results	BU
20/04/12	Human Genome Sciences : to Sponsor Conference Call to Discuss First Quarter 2012 Financial Results	BU
19/04/12	Human Genome Sciences : Announces Unsolicited Offer from GlaxoSmithKline; HGS Board of Directors Authorizes Exploration of Strategic Alternatives	BU
03/04/12	Human Genome Sciences : FYI from Human Genome Sciences: GlaxoSmithKline Announces Further Data from Phase 3 Trials of Albiglutide	BU
20/03/12	Human Genome Sciences : NEW SURVEY REVEALS LUPUS COMMUNICATION GAP AS MANY PATIENTS REMAIN SILENT ON TRUE IMPACT OF DISEASE	PU